Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis
Autor: | Mi Liu, Li-qiong Wang, Hui-min Mao, Hua Qu, Dazhuo Shi |
---|---|
Rok vydání: | 2017 |
Předmět: |
medicine.medical_specialty
business.industry General Medicine 030204 cardiovascular system & hematology medicine.disease Placebo law.invention Angina Clinical trial 03 medical and health sciences 0302 clinical medicine Complementary and alternative medicine Randomized controlled trial law Meta-analysis Internal medicine Relative risk Cardiac syndrome X medicine Physical therapy Pharmacology (medical) 030212 general & internal medicine Myocardial infarction business |
Zdroj: | Chinese Journal of Integrative Medicine. 24:296-303 |
ISSN: | 1993-0402 1672-0415 |
DOI: | 10.1007/s11655-017-2762-8 |
Popis: | To evaluate the efficacy and safety of Tongxinluo Capsule (通心络胶囊, TXL) for patients with cardiac syndrome X (CSX). Randomized controlled trials (RCTs) regarding TXL in the treatment of CSX were searched in Chinese Biomedicine Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, PubMed, EMBASE, Cochrane Central Register of Controlled Trial, websites of the Chinese and International Clinical Trial Registry platform up to June 30, 2015. The intervention was either TXL alone or TXL combined with conventional treatment, while the control intervention was conventional treatment with or without placebo. Data extraction, methodological quality assessment and data analyses were performed according to the Cochrane criteria. The primary outcome was a composite event of death, acute myocardial infarction (AMI), angina requiring hospitalization, revascularization, and heart failure. The secondary outcome measures were angina symptom improvement, electrocardiograph (ECG) improvement, and serum endothelin-1 (ET-1) level. The adverse events were also recorded. RevMan 5.3 software was applied for data analyses. Twelve RCTs (696 patients) were included. Compared with conventional treatment, the addition of TXL to conventional treatment showed some benefits on relieving angina symptoms [risk ratio (RR): 1.46, 95% confidence interval (CI) (1.25, 1.71), P |
Databáze: | OpenAIRE |
Externí odkaz: |